For decades, the weight loss market has been a highly profitable industry. Dietary companies, books of miraculous solutions and dietary supplements that should activate metabolism have promised amazing results. However, the reality is quite different, since most of these ‘solutions’ have proven to be ineffective and, in the worst case, harmful to the individual’s health. Despite this, many have continued to try to lose weight at all costs, in parallel with the increase in obesity globally.
Currently, about 650 million people suffer from this disorder, which is not only an aesthetic concern, but also related to a wide spectrum of disabling or fatal diseases, including heart problems, liver damage and diabetes. It is therefore essential to pay attention to sources of information and promote a professional approach to weight loss, which always takes into account the health and well-being of those who use it.
The market for obesity therapies has already reached 15 billion dollars, and was previously expected to grow to 32 billion dollars by 2030, with a CAGR of 10.1%. However, Novo Nordisk’s recent successful launch of Wegovy has led to new projections that indicate a possible market growth of up to 50 billion dollars by 2030. This is due to the increasingly widespread trend of moving away from traditional behavioral and surgical therapies for obesity, towards the use of new classes of drugs, based on our growing understanding of human metabolism. These drugs have proven to be able to modify patients’ appetite and adipose tissue generation, opening up new possibilities in the fight against obesity. Some analysts have already defined obesity as the ‘new hypertension’, and great successes are expected for the pharmaceutical category
that treats it.
Companies in the treatment of obesity 2023: the best
Given the importance of the topic in the pharmaceutical industry, we have selected companies based on the maturity of their products, starting with those already marketed, to have a clear vision of the market and of possible developments with the introduction of new therapeutic classes in the future.
Novo Nordisk is a leader in the field of diabetes therapies, accounting for 79% of its current revenues, while obesity represents only 9%. However, the recent introduction of Wegovy, a weight-loss drug that mimics a weight-related hormone, was surprisingly successful with an 84 percent growth in 2022. The success of Wegovy has led to a rise in Novo Nordisk’s sales growth expectations for 2023 and is attracting the attention of
major investors.
Eli Lilly, another leader in the field of diabetes, is developing an obesity drug called Mounjaro, which has had promising results in its preliminary clinical trials. We suspect that Mounjaro could become Wegovy’s serious competitor in the obesity market
.
Altimmune, Inc. He is still developing his obesity drug pemvidutide, but the molecule acts on GLP-1 and Glucagon, offering the hope of mimicking the effect of exercise to reduce hunger. Even if the company is still at an early stage compared to the other two, if the obesity treatment is successful, it could provide a huge boost to the company’s value
.
It’s important to note that there are possible side effects with all of these obesity treatments and that it’s highly recommended that you speak to a medical professional before using them. However, these products represent a great market opportunity and investors should keep an eye on the progression of the three companies in this field
.
